secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-RAD LABORATORIES, INC. (BIO)
CIK:        0000012208
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0000012208-23-000045
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Rad Q1 sales down 3.3% to $676.8M; operating income drops 57.7% to $61.9M
-----------------------------------------------------------------------------

- Net sales $676.8M, down 3.3%; currency-neutral down 0.3%; ex-COVID up 6.1%.
- GAAP diluted EPS $2.32 vs loss of $112.50; operating income $61.9M vs $146.4M.
- Life Science sales $323.6M, down 6.8% (ex-COVID up 9.6% on qPCR, western blotting, ddPCR).
- Clinical Diagnostics sales $352.1M flat; currency-neutral up 2.8% ex-COVID up 3.1%.
- COVID sales dropped to $2.6M from $45M; gross margin fell to 53.5% from 57.5%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/12208/000001220823000045/0000012208-23-000045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/12208/000001220823000045/bio-20230504.htm
  HTML page:      https://secwatch.observer/filing/0000012208-23-000045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer